Lymphomas represent the most frequent hematologic malignancies.  18F-FDG PET imaging holds a crucial role for diagnosis, staging and monitoring of treatment response. Thanks to radiomics, the number of parameters extracted from PET images is notably increased, among which novel biomarkers with clinical relevance might emerge. At IEO, the Radiomic Team is investigating the role of PET radiomics in the biologic characterization and prognostic stratification of Diffuse Large B-Cell Lymphoma. Promising results have been obtained in studies aimed at refining current prognostic stratification algorithms. Moreover, ongoing studies produced interesting data on the association between radiomic signatures and specific metabolic profiles. If confirmed, PET radiomics analysis applied at baseline prior to systemic therapy, might improve the stratification of the risk of recurrence, allowing non-invasive characterization of lymphoma metabolism and the identification of possible of patients who might less likely respond to treatment. Additional PET radiomics studies are on-going in Hodgkin lymphoma in a multicenter setting.